Seagen logged a 0.0% change during today's morning session, and is now trading at a price of $228.94 per share. The S&P 500 index moved 0.0%. SGEN's trading volume is 2,823,444 compared to the stock's average volume of 1,560,253.
Seagen trades 0.02% away from its average analyst target price of $228.91 per share. The 11 analysts following the stock have set target prices ranging from $228.0 to $229.0, and on average have given Seagen a rating of hold.
If you are considering an investment in SGEN, you'll want to know the following:
-
Seagen has moved 73.3% over the last year, and the S&P 500 logged a change of 16.2%
-
Based on its trailing earnings per share of -4.01, Seagen has a trailing 12 month Price to Earnings (P/E) ratio of -57.1 while the S&P 500 average is 15.97
-
SGEN has a forward P/E ratio of -116.2 based on its forward 12 month price to earnings (EPS) of $-1.97 per share
-
The company has a price to earnings growth (PEG) ratio of 0.54 — a number near or below 1 signifying that Seagen is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 16.93 compared to its sector average of 4.08
-
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
-
Based in Bothell, the company has 3,256 full time employees and a market cap of $43.19 Billion.